- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04780165
Efficacy and Tolerability of Blephademodex Wipes
March 1, 2021 updated by: Laboratoires Thea
Prospective, Open Label, Multicenter Trial to Investigate the Efficacy and Tolerability of Blephademodex Wipes in Patients With Demodex Blepharitis
Primary Objective
- To evaluate efficacy of Blephademodex eyelid hygiene wipe treatment with a subsequent maintenance period with Blephaclean lid cleansing wipes in Demodex blepharitis, as assessed by the change in ocular symptoms by a Global Discomfort Scale (GDS).
Secondary Objectives
- To evaluate the efficacy of Blephademodex eyelid hygiene wipe treatment in Demodex blepharitis as assessed by the change alone and in combination with a subsequent maintenance period of treatment with Blephaclean eyelid cleansing wipes ocular symptoms by: adapted TOSS; SANDE; specific blepharitis symptoms; Demodex count; ocular surface redness (Efron scale); lid margin redness/swelling (Efron / custom scale); Dandruff coverage at bases of eyelashes; ocular surface staining (Oxford scale; corneal only)
- To evaluate subject and physician satisfaction with Blephademodex eyelid hygiene wipes
- To evaluate ease of use for Blephademodex eyelid hygiene wipes
- Adverse events are documented and analyzed.
Study Overview
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Heidelberg, Germany, 69121
- Consultation office
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient > 18 years old, all genders
- Able to read, to write and to fully understand German language
- Good general health as determined by the investigator by medical history and physical appearance
- Provision of written informed consent prior to inclusion
- Moderate to Severe Blepharitis - grade ≥ 2 (Efron Scale)
- Global discomfort score (GDS) ≥ 4
- Proof of demodex infestation by at least ONE of the following:Demodex visible after lash manipulation;Cylindrical dandruff along the lash line; Lid margin itching; Madarosis
Exclusion Criteria:
- History of ocular trauma, ocular infection or intra-ocular inflammation within the 3 months before screening visit
- History of ocular refractive surgery and any other ocular surgeries within 3 months before screening visit
- History of ocular allergy or ocular herpes within the 3 months before screening visit
- History of inflammatory corneal ulcer within the 6 months before screening visit
- Sjogren syndrome or any other rheumatologic disease related dry eye
- Concurrent treatment with other eye drops (anti-infectives, steroids, prostaglandins (but artificial tears are ok).
- Specific Exclusion Criteria for Women:Patient who verbally confirms pregnancy or lactation; Childbearing potential woman who is not using a reliable method of contraception (oral contraceptive, intra-uterine device, subcutaneous contraceptive implant, vaginal ring, patch or condom) and is not surgically sterilised
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single-arm
|
During the first 28 days of the trial, subjects will use one Blephademodex® eyelid hygiene wipe every evening per eye to clean the eyelids of both their eyes.
At the start of the second period the Investigator will assess based on the GDS if the condition is resolved and manage accordingly: subjects will either continue with this regime if GDS is unchanged (further treatment phase) or revert to Blephaclean wipes every evening instead (maintenance phase), again to clean the eyelids of both their eyes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global Discomfort Score
Time Frame: Day 28
|
Change from Baseline at Day 28 The Global (overall) discomfort score (GDS) consists of a single question, which can be answered by the subject by choosing a value between 0 (no discomfort) and 10 (worst discomfort): Thinking about today, how would you rate the discomfort of your eyes?
|
Day 28
|
Global Discomfort Score
Time Frame: Day 56
|
Change from D28 at Day 56
|
Day 56
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Specific Blepharitis symptoms
Time Frame: Day 56
|
Symptoms will be rated by the patient on the day of visit using 10-grade scales (0 = none to 10 = severe) for each of the following items Severity of any eyelid itching today / Severity of lid redness today / Severity of eyelid swelling today / How severe was the eyelid crusting this morning when you woke up? / How severe is missing lashes today?
|
Day 56
|
adapted Total Ocular Symptom Score (TOSS)
Time Frame: Day 56
|
8-item questionnaire with an overall score ranging from 0 ("none of the time") to 4 ("all of the time").
It contains of a single question concerning the frequency with which 8 different symptoms (itchy eyelids, eyelid redness, red eyes generally, swollen (puffy) eyes, tearing (eyes watering), crusting around the lashes, burning or stinging sensations and noticed eyelash loss) were experienced in the course of a week.
|
Day 56
|
Symptom Assessment in Dry Eye (SANDE)
Time Frame: Day 56
|
Comprised of two questions: 1) How often do your eyes feel dry and/or irritated?
And 2) How severe you feel your symptoms of dryness and/or irritation are?
This questionnaire uses a 100 mm horizontal line as visual analogue scale (VAS) for each question to assess ocular discomfort and/or dryness experienced by the patients.
In the SANDE questionnaire, frequency of symptoms ranges from "rarely" to "all of the time" and the severity of symptoms ranges from "very mild" to "very severe".
|
Day 56
|
Demodex count
Time Frame: Day 56
|
Sideways 'pull' on 10 eyelashes - upper or lower lashes Extent (mites present?
yes or no) and Severity/Intensity (1=1 tail; 2=2 tails; 3 =2+tails)
|
Day 56
|
Ocular surface redness
Time Frame: Day 56
|
Efron scale
|
Day 56
|
Lid margin redness/swelling
Time Frame: Day 56
|
Efron/custom scale
|
Day 56
|
Cylindrical dandruff
Time Frame: Day 56
|
Lash line coverage (%) and severity (mild/moderate/severe)
|
Day 56
|
Ocular surface staining
Time Frame: Day 56
|
Oxford scale; corneal only
|
Day 56
|
Physician's impression and patient impression
Time Frame: Day 56
|
Answer the item 'the treatment has been sufficiently effective' on a 4-point scale (strongly disagree, disagree, agree, strongly agree)
|
Day 56
|
Tolerability of the wipes
Time Frame: Day 56
|
Tolerability assessment by the physician and patient (0 = intolerable; 1 = somewhat tolerable; 2 = tolerable; 3 = fully tolerable)
|
Day 56
|
Visual acuity
Time Frame: Day 56
|
Snellen eye chart
|
Day 56
|
Assessment of ease of use
Time Frame: Day 56
|
as experienced by the subjects, rated on a five-point scale of "Very Difficult" to "Very Easy".
|
Day 56
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 11, 2019
Primary Completion (Actual)
March 13, 2020
Study Completion (Actual)
May 14, 2020
Study Registration Dates
First Submitted
September 23, 2020
First Submitted That Met QC Criteria
March 1, 2021
First Posted (Actual)
March 3, 2021
Study Record Updates
Last Update Posted (Actual)
March 3, 2021
Last Update Submitted That Met QC Criteria
March 1, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LTPIVBDX19
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Demodex Blepharitis
-
Tarsus Pharmaceuticals, Inc.RecruitingDemodex BlepharitisUnited States
-
Tarsus Pharmaceuticals, Inc.Active, not recruitingMeibomian Gland Dysfunction | Blepharitis | Demodex Infestation of Eyelid | Demodectic BlepharitisUnited States
-
Tarsus Pharmaceuticals, Inc.CompletedMeibomian Gland Dysfunction | Blepharitis | Demodex InfestationUnited States
-
National Taiwan University HospitalUnknownRosacea | Meibomian Gland Dysfunction | Blepharitis | Demodex Infestation | Pityriasis FolliculorumTaiwan
-
NTC srlCompletedBilateral Blepharitis (Disorder)Italy
-
Istanbul University - Cerrahpasa (IUC)Koç UniversityCompleted
-
Shaare Zedek Medical CenterRecruiting
-
University of California, Los AngelesTerminatedAnterior BlepharitisUnited States
-
Istanbul University - Cerrahpasa (IUC)Koç UniversityCompleted
-
Sun Pharmaceutical Industries LimitedCompletedActive, Symptomatic BlepharitisUnited States
Clinical Trials on Blephademodex
-
University of WaterlooCompleted